Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

October 4, 2018

Primary Completion Date

July 8, 2023

Study Completion Date

September 18, 2026

Conditions
Pleural Malignant Mesothelioma
Interventions
BIOLOGICAL

Anetumab Ravtansine

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

OTHER

Pharmacological Study

Correlative studies

Trial Locations (33)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

21201

University of Maryland/Greenebaum Cancer Center, Baltimore

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

27710

Duke University Medical Center, Durham

33136

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

33146

UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables

33176

UM Sylvester Comprehensive Cancer Center at Kendall, Miami

33180

UM Sylvester Comprehensive Cancer Center at Aventura, Aventura

33324

UM Sylvester Comprehensive Cancer Center at Plantation, Plantation

33442

UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach

35233

University of Alabama at Birmingham Cancer Center, Birmingham

40536

University of Kentucky/Markey Cancer Center, Lexington

55905

Mayo Clinic in Rochester, Rochester

60611

Northwestern University, Chicago

60637

University of Chicago Comprehensive Cancer Center, Chicago

63110

Washington University School of Medicine, St Louis

63129

Siteman Cancer Center-South County, St Louis

63141

Siteman Cancer Center at West County Hospital, Creve Coeur

63376

Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters

75390

UT Southwestern/Simmons Cancer Center-Dallas, Dallas

80045

UCHealth University of Colorado Hospital, Aurora

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

85054

Mayo Clinic Hospital in Arizona, Phoenix

85259

Mayo Clinic in Arizona, Scottsdale

90033

Los Angeles General Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope Comprehensive Cancer Center, Duarte

92093

UC San Diego Moores Cancer Center, La Jolla

92663

USC Norris Oncology/Hematology-Newport Beach, Newport Beach

32224-9980

Mayo Clinic in Florida, Jacksonville

02114

Massachusetts General Hospital Cancer Center, Boston

02215

Dana-Farber Cancer Institute, Boston

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03126630 - Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma | Biotech Hunter | Biotech Hunter